Real-World Data on Sativex (THC:CBD Spray) for MS Spasticity Across Three Countries
Registry data from over 900 patients in the UK, Germany, Switzerland, and Spain showed that the THC:CBD oromucosal spray Sativex had a positive risk-benefit profile with no evidence of addiction, abuse, or misuse during long-term use.
Quick Facts
What This Study Found
Since Sativex became available in European countries in 2010 for treatment-resistant multiple sclerosis spasticity, real-world data has been collected through registry and observational studies across multiple countries.
The most recent analysis of registry data from over 900 patients in the UK, Germany, and Switzerland showed long-term continuation rates of 68% at one year, with an average dose of 5.4 sprays per day. No new safety concerns emerged, and adverse events of special interest for a cannabis-based medicine were limited.
A separate prospective study in Spain involving 207 patients from 13 specialized MS centers produced closely matching results: 64.7% continuation rate at one year, average dose of 6.6 sprays per day, and a similar safety profile with no evidence of addiction, abuse, or misuse.
Key Numbers
Registry data (UK/Germany/Switzerland): 68% one-year continuation rate, mean dose 5.4 sprays/day, 900+ patients. Spain study: 64.7% one-year continuation rate, mean dose 6.6 sprays/day, 207 patients from 13 centers. No evidence of addiction, abuse, or misuse in either dataset.
How They Did This
Two data sources were examined: a retrospective registry study collecting safety data from patients in the UK, Germany, and Switzerland (900+ patients), and a prospective safety study from 13 specialized MS centers in Spain (207 patients). Both tracked continuation rates, dosing, and adverse events.
Why This Research Matters
Clinical trials show a drug works under controlled conditions. Real-world evidence shows whether it works in everyday medical practice, where patients have more complex health situations and less supervision. The consistency of these results across four countries strengthens the case that Sativex is both effective and well-tolerated for MS spasticity.
The Bigger Picture
The convergence of safety and effectiveness data across different countries, healthcare systems, and study designs provides robust real-world validation of THC:CBD as a therapeutic option. The absence of addiction or abuse signals is particularly notable given ongoing concerns about cannabis-based medicines.
What This Study Doesn't Tell Us
Observational studies lack the control of randomized trials and cannot account for all confounding factors. Patients who continued treatment may differ systematically from those who stopped. The studies focused on MS spasticity and cannot be generalized to other conditions.
Questions This Raises
- ?Would these continuation rates and safety profiles hold over periods longer than one year?
- ?How do these real-world outcomes compare to other MS spasticity treatments?
Trust & Context
- Key Stat:
- 68% of patients still using Sativex at one year, with no addiction signals
- Evidence Grade:
- Large real-world dataset across multiple countries, but observational design without randomization or placebo controls.
- Study Age:
- Published in 2016 with data from 2010 onward. Sativex has since accumulated additional years of real-world evidence.
- Original Title:
- THC:CBD in Daily Practice: Available Data from UK, Germany and Spain.
- Published In:
- European neurology, 75 Suppl 1, 1-3 (2016)
- Authors:
- Fernández, Óscar
- Database ID:
- RTHC-01152
Evidence Hierarchy
Watches what happens naturally without intervening.
What do these levels mean? →Frequently Asked Questions
Is Sativex addictive?
In registry data from over 1,100 patients across four European countries, there was no evidence of addiction, abuse, or misuse during long-term treatment.
How many patients stay on Sativex long-term?
Approximately 65-68% of patients were still using Sativex at the one-year mark, suggesting most patients find meaningful benefit.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-01152APA
Fernández, Óscar. (2016). THC:CBD in Daily Practice: Available Data from UK, Germany and Spain.. European neurology, 75 Suppl 1, 1-3. https://doi.org/10.1159/000444234
MLA
Fernández, Óscar. "THC:CBD in Daily Practice: Available Data from UK, Germany and Spain.." European neurology, 2016. https://doi.org/10.1159/000444234
RethinkTHC
RethinkTHC Research Database. "THC:CBD in Daily Practice: Available Data from UK, Germany a..." RTHC-01152. Retrieved from https://rethinkthc.com/research/fernandez-2016-thccbd-in-daily-practice
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.